Leukocyte receptor tyrosine kinase (LTK) is a gene that encodes a protein that is a member of the ros/insulin receptor family of tyrosine kinases. Missense mutations, silent mutations, nonsense mutations, and frameshift deletions are observed in cancers such as skin cancer, colon cancer, and endometrial cancer.
LTK is altered in 2.43% of all cancers with breast invasive ductal carcinoma, prostate adenocarcinoma, pancreatic adenocarcinoma, adenocarcinoma of unknown primary, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in LTK are LTK G269A (0.34%), LTK F218I (0.28%), LTK N257T (0.53%), LTK A13fs (2.08%), and LTK A214fs (0.22%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.